DKSC Dakshidin Corporatio

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Breaking Down Financial Barriers with AI In the hustle of Money20/20 USA in Las Vegas, TomoIQ dropped a financial bombshell with their latest tool, Money Finder. This isn't just another app in the sea of fintech solutions. Nope, this one promises to cut through the complexities that most folks face when trying to get their financial house in order. An AI Buddy for...

Collagen Solutions Front and Center First up, a little chat about collagen might be in order. For folks not tied into the science side, it sounds like a trendy wellness potion. But here comes GELITA at SupplySide Global 2026, showing it's the real McCoy. Nestled in Booth #4565, they're laying out a spread of next-gen collagen innovations aimed at everything from wound...

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Pushing the Boundaries with AI in Drug Discovery It seems some smart folks over in South Korea are giving the pharma game a fresh twist, pitting artificial intelligence against viral invaders in a newfangled brawl. Professors from Korea University have managed to blend AI's computing prowess with good ol' lab doggedness to sniff out potential antiviral compounds. The...

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...

Flashing Billions: Minting Millionaires at Breakneck Speed It sounds like something out of an 80s movie: every single day, over 1,200 folks in the United States become millionaires. Yep, you heard right. The UBS Global Wealth Report 2026 threw that number out, and it sure caught my attention. It's not everyday you hear about the U.S. cranking out millionaires like they're...

Akeso Moves Forward with Promising Cancer Therapy Trials Akeso Biopharma is excited to share fantastic news regarding its latest clinical endeavors in the realm of cancer treatment. The company has successfully enrolled the first patient in the AK112-309 trial, a pivotal Phase III study designed to evaluate the efficacy of ivonescimab in combination with another regimen...

Quanex Building Products Announces Quarterly Dividend HOUSTON — Quanex Building Products Corporation (NX) is pleased to announce that its Board of Directors declared a quarterly cash dividend of $0.08 per share on its common stock. This dividend is scheduled to be paid to shareholders of record on a specified date, indicating the company's commitment to rewarding its...

Trump Demands Drug Firms Reveal COVID Vaccine Data Former President Donald Trump has issued a call to pharmaceutical companies to provide concrete evidence regarding the effectiveness of their COVID-19 drugs, particularly emphasizing the need for transparency surrounding their vaccine data. Transparency in Pharmaceuticals On his social media platform, Trump urged these...

AECOM Technology Stock Peaks at $108.26 AECOM Technology Corporation has recently achieved a major milestone in the stock market, reaching an impressive high of $108.26. This achievement not only reflects the robust growth of the infrastructure consulting firm but also represents a 43.14% increase in its stock value over the past year. Investors have been showing strong...

China Resumes U.S. Soybean Purchases Amid Market Changes Recent reports indicate that China has made its initial purchase of U.S. soybeans from the current year’s harvest, marking the end of a prolonged boycott. This significant development comes just ahead of a highly anticipated summit between U.S. President Donald Trump and Chinese President Xi Jinping. Market...